This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of pulmonary hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Diuretics are needed to control oedema from right heart failure and home oxygen to correct hypoxia.
  • Anticoagulation is recommended in pulmonary arterial hypertension (PAH) and is essential for patients with chronic thromboembolic pulmnary hypertension (CTEPH).
    • Primary (idiopathic) pulmonary hypertension is treated with anticoagulants (because it is virtually impossible to rule out persistent micro-emboli as the cause).
  • Calcium channel blockers are indicated in a small subset of patients with idiopathic hypertension who show a vasoreactive response at right heart catheterisation.
  • In patients with group 1 pulmonary arterial hypertension (idiopathic PAH, PAH associated with connective tissue disease - predominantly seen with scleroderma) (1).
    • Specific drugs have been found to be beneficial in randomised controlled trials with improvement in symptoms, delayed disease progression and improved survival.
    • There are three main drug classes: prostanoids delivered iv, by nebuliser or subcutaneous (eg epoprostenol, iloprost, treprostinil), endothelin receptor antagonists (eg bosentan, ambrisentan), and phosphodiesterase inhibitors (eg sildenafil, tadalafil).
      • These drugs are only prescribed through the designated centres.
      • Side effects include flushing, headaches, gastro-intestinal disturbance and hypotension.
      • Endothelin receptor antagonists require monthly liver function monitoring.

CTEPH

  • Treatment of choice for patients with CTEPH is pulmonary endarterectomy (PEA) surgery.
  • Lifelong anticoagulation is also recommended; antiplatelet therapy is not an alternative.
  • Majority of patients can be cured with normalisation of pulmonary pressure following surgery with improvement in symptoms and prognosis, with a > 90% 5 year survival.
  • Patients unsuitable for pulmonary endarterectomy surgery and patients who still have residual PH following pulmonary endarterectomy surgery might be considered for treatment with the drugs described above.

Endothelin receptor antagonists

  • A systematic review concluded (1)
    • endothelin receptor antagonists probably increase exercise capacity, improve World Health Organization functional class (a measurement
      of how severe a person's pulmonary hypertension symptoms are), and may improve death rates and symptoms in people with PAH;
      however they may also increase the risk of liver damage, although this was rare.

In selected patients who have class 4 symptoms despite optimal medical therapy, bilateral lung or heart lung transplantation may be considered. The 5 year survival following transplantation is approximately 50-60%.

Notes:

  • A meta-analysis showed evidence an improvement of survival in the patients treated with the targeted therapies approved for pulmonary arterial hypertension (2).
    • With respect to the effects of the different classes of drugs (prostanoids, thromboxane synthase inhibitors, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors), no statistically significant between-group heterogeneity emerged in subgroup analyses in total mortality or between the subgroups testing each of the treatments.
  • The clinical classification of pulmonary hypertension is helpful in understanding the different aetiology and determining treatment (3):
    • Group 1 Pulmonary arterial hypertension (PAH)
      • idiopathic PAH
      • PAH associated with connective tissue disease: predominantly seen with scleroderma
    • Group 2 Left heart disease
      • PH associated with left heart dysfunction, systolic, diastolic or valve disease
    • Group 3 Lung disease
      • PH in patients with COPD or interstitial lung disease
    • Group 4 Chronic thromboembolic pulmonary hypertension
    • Group 5 Unclear and multifactorial mechanisms
      • Rare diseases.
  • World Health Organization classification functional status in primary pulmonary hypertension:
    • class I - no limitation on physical activity functional
    • class II - slight limitation functional class
    • III - pronounced limitation functional
    • class IV - inability to carry out any physical activity without symptoms.

References:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.